Roche Petrelintide Data Recasts Obesity Opportunity And Pipeline Growth Story
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million…
Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
F. Hoffmann-La Roche Ltd Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7%…
Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
F. Hoffmann-La Roche Ltd Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7%…
Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
F. Hoffmann-La Roche Ltd Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7%…
![[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth](https://www.europesays.com/ch/wp-content/uploads/2026/02/84b0110bbf60eb8397db0461bc3549c4-380x220.png)
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity
F. Hoffmann-La Roche Ltd A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of…